Novel human lymph node-derived matrix supports the adhesion of metastatic oral carcinoma cells
A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation
Latest collections open to submissions
NEW: Diet and physical activity during and after cancer treatment
Guest Edited by Nicolas H. Hart and Dominic O’Connor
NEW: Immunology and immunotherapy in solid cancers
Guest Edited by Zachary C. Hartman and Daniel Smrz
New breakthroughs and future directions in the treatment of hematological malignancies
Guest Edited by Ajay Abraham and Ahmet Emre EÅŸkazan
Editors' Picks
Trending BMC Cancer Articles
Click here to view which Articles have been shared most in the last month!
Articles
-
-
Establishing a prognostic model based on immune-related genes and identification of BIRC5 as a potential biomarker for lung adenocarcinoma patients
-
Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound
-
Small molecule targeting of the p38/Mk2 stress signaling pathways to improve cancer treatment
-
Clinical characteristics of peripherally inserted central catheter-related complications in cancer patients undergoing chemotherapy: a prospective and observational study
-
M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide
-
An electronic application for rapidly calculating Charlson comorbidity score
-
Does colon cancer ever metastasize to bone first? a temporal analysis of colorectal cancer progression
-
Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression
-
Predictors of recurrence free survival for patients with stage II and III colon cancer
Targeted Therapies for Cancer
Guest edited by Prof. Min Li and Dr. Yanis Boumber
Open for submissions
Microbiome and Cancer
Guest edited by Christopher Staley, Jacques Ravel, Sean Devlin
Open for submissions
Cross journal collection: Advances in CAR-T immunotherapy
Guest edited by Profs Marko Radic, Djordje Atanackovic and Tim Luetkens
Collection published: 30 June 2020
Cross journal collection: Precision Oncology
Collection published: 28 August 2019
Browse all BMC Cancer collection contributions
MULISARC trial: molecular profiling of advanced soft-tissue sarcomas
THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy
Learn more about study protocols at BMC Cancer here
Aims and Scope
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions in broad areas of cancer research including molecular and cellular biology, genetics, epidemiology, and clinical trials. Learn more about our scope here.
Urological Cancers Awareness Month
Urological Cancers Awareness Month runs for the whole of September. We hope you will enjoy reading the following article recently published in BMC Cancer highlighting the importance of biomarkers in for urothelial bladder cancer patient stratification to help avoiding unnecessary interventions whilst indicating aggressive measures when required.
Become an Editorial Board Member
We are recruiting new Editorial Board Members.
Read MoreBMC Cancer is celebrating its 20th anniversary!
Since launching in 2001, we've become established as the largest open access oncology journal in our field. We're proud of our history of making cancer research and methods available to all. We have been looking back at our achievements and highlighted some of the most influential research published in the journal over the past two decades.
BMC Series Blog
-
-
Highlights of the BMC Series – August 2023
19 September 2023
-
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
Annual Journal Metrics
-
2022 Citation Impact
3.8 - 2-year Impact Factor
4.3 - 5-year Impact Factor
1.166 - SNIP (Source Normalized Impact per Paper)
1.137 - SJR (SCImago Journal Rank)2022 Speed
9 days submission to first editorial decision for all manuscripts (Median)
148 days submission to accept (Median)2022 Usage
7,665,706 downloads
11,097 Altmetric mentions
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication